SKYE Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.307

+5.31%

-0.342

+22.14%

-0.268

-40%

Estimates Revision

The market is revising No Change the revenue expectations for Skye Bioscience, Inc. (SKYE) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -38.95%.

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-38.95%

In Past 3 Month

7 Analyst Rating

Wall Street analysts forecast SKYE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SKYE is 9.80 USD with a low forecast of 2.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

2 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

2.00

Averages

9.80

High

20.00

Current: 0.000

Low

2.00

Averages

9.80

High

20.00

H.C. Wainwright

Ananda Ghosh

Buy

initiated

$20

2025-09-30

Reason

H.C. Wainwright

Ananda Ghosh

Price Target

$20

2025-09-30

initiated

Buy

Reason

H.C. Wainwright analyst Ananda Ghosh initiated coverage of Skye Bioscience with a Buy rating and $20 price target. The firm believes the company's nimacimab can introduce a new mechanism of longstanding interest to obesity clinicians. Nimacimab is a peripherally restricted monoclonal antibody targeting the CB1 receptor, designed to deliver the metabolic benefits of CB1 blockade without the psychiatric side effects that derailed earlier small molecule antagonists, the analyst tells investors in a research note. H.C. Wainwright views Sykes shares as undervalued at current levels.

Evercore ISI

Michael DiFiore

Outperform

initiated

$10

2025-08-14

Reason

Evercore ISI

Michael DiFiore

Price Target

$10

2025-08-14

initiated

Outperform

Reason

Evercore ISI analyst Michael DiFiore initiated coverage of Skye Bioscience with an Outperform rating and $10 price target.

Evercore ISI

Outperform

initiated

$10

2025-08-14

Reason

Evercore ISI

Price Target

$10

2025-08-14

initiated

Outperform

Reason

As previously reported, Evercore ISI initiated coverage of Skye Bioscience with an Outperform rating and $10 price target. Nimacimab is the \"only weekly SC large molecule CB1 inhibitor in development,\" says the analyst, who sees the drug having the potential to \"fill critical gaps in obesity care.\" The 26-week Phase 2a readout due in late Q3 or early Q4 will be \"the next major test,\" the analyst added.

Oppenheimer

Outperform

Perform

downgrade

$21 -> $17

2025-05-12

Reason

Oppenheimer

Price Target

$21 -> $17

2025-05-12

downgrade

Outperform

Perform

Reason

Oppenheimer lowered the firm's price target on Skye Bioscience to $17 from $21 and keeps an Outperform rating on the shares. The firm notes the company reported Q1 results with $11.8M OpEx and $59.2M cash providing expected runway through Q1 2027 and supporting execution of Phase 2a CBeyond and manufacturing for Phase 2b. Oppenheimer looks forward to top-line data for CBeyond in late-Q3/early-Q4, as Skye previously announced that ahead-of-schedule enrollment would eliminate the need for an interim analysis. Regarding CBeyond trial extension, it sees longer-term dosing and follow-up as potentially derisking for nimacimab ahead of a dose-ranging Phase 2b.

Citizens Capital Markets

Jonathan Wolleben

Buy

Reiterates

$15

2025-03-21

Reason

Citizens Capital Markets

Jonathan Wolleben

Price Target

$15

2025-03-21

Reiterates

Buy

Reason

Craig-Hallum

Albert Lowe

Strong Buy

Maintains

$18 → $14

2025-03-21

Reason

Craig-Hallum

Albert Lowe

Price Target

$18 → $14

2025-03-21

Maintains

Strong Buy

Reason

Craig-Hallum analyst Albert Lowe lowered the firm's price target on Skye Bioscience to $14 from $18 and keeps a Buy rating on the shares. The firm notes that due to enrollment of the ongoing Phase II study of nimacimab in obesity completing ahead of schedule, the company is removing the previously planned Q2 2025 interim analysis in favor of moving up the topline readout to September/October, from Q4 2025 previously. While this change makes the first look at the obesity data slightly later, the topline dataset for this important catalyst will be more robust, containing 26-week data on all 136 patients, Craig-Hallum adds. The benchmark for success will be an 8% weight loss with Albert focused on improvements in GI tolerability and lean mass preservation relative to GLP1 therapies. In addition, an open-label extension was added to increase the treatment time to 52 weeks, giving nimacimab sufficient time to show its full weight loss potential in future updates.

Valuation Metrics

The current forward P/E ratio for Skye Bioscience Inc (SKYE.O) is -0.74, compared to its 5-year average forward P/E of -2.31. For a more detailed relative valuation and DCF analysis to assess Skye Bioscience Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.31

Current PE

-0.74

Overvalued PE

1.27

Undervalued PE

-5.89

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

SKYE News & Events

Events Timeline

No data

News

7.0

01-08Globenewswire

Skye Bioscience Shareholders File Class Action Alleging Misleading Statements

7.0

01-08Globenewswire

Skye Bioscience Faces Class Action for Alleged Securities Fraud, Investors Can Claim Damages

7.0

01-07PRnewswire

Skye Bioscience Faces Class Action Lawsuit with January 16 Deadline

People Also Watch

Frequently Asked Questions

What is Skye Bioscience Inc (SKYE) stock price today?

The current price of SKYE is 1.05 USD — it has decreased -5.41 % in the last trading day.

What is Skye Bioscience Inc (SKYE)'s business?

Skye Bioscience, Inc. is a clinical-stage biotechnology company. The Company is focused on development of next-generation molecules that modulate G-protein coupled receptors to treat obesity, overweight, and related conditions. The Company’s lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1). The Company is also focused on its Phase IIa clinical trial, CBeyond, for nimacimab. The CBeyond clinical trial includes approximately 136 patients, 16 clinical trial sites and a combination arm with a GLP-1 receptor agonist to assess differences in weight loss, body composition, and other attributes. The CB1 receptor is one of the receptors in the endocannabinoid system (ECS) and plays a significant role both in the central nervous system (CNS) and peripheral tissues. The Company's Phase II study in obesity for nimacimab, is a negative allosteric modulating antibody that peripherally inhibits CB1.

What is the price predicton of SKYE Stock?

What is Skye Bioscience Inc (SKYE)'s revenue for the last quarter?

Skye Bioscience Inc revenue for the last quarter amounts to -13.26M USD, increased 39.30 % YoY.

What is Skye Bioscience Inc (SKYE)'s earnings per share (EPS) for the last quarter?

Skye Bioscience Inc. EPS for the last quarter amounts to -13364375.00 USD, increased 97.08 % YoY.

What changes have occurred in the market's expectations for Skye Bioscience Inc (SKYE)'s fundamentals?

How many employees does Skye Bioscience Inc (SKYE). have?

Skye Bioscience Inc (SKYE) has 11 emplpoyees as of January 09 2026.

What is Skye Bioscience Inc (SKYE) market cap?

Today SKYE has the market capitalization of 33.66M USD.